Roche reports Phase 3 data on sefaxersen for kidney disease
Tweet Send to a Friend
Roche announced Phase 3 trial results for investigational drug sefaxersen, showing a statistically significant 43.1% reduction in proteinuria relative to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




